System and method for affecting intestinal microbial flora

• US 10,159,699 B2
• Filed: 01/15/2014
• Issued: 12/25/2018
• Est. Priority Date: 01/15/2013
• Status: Active Grant

• Current Assignee: MetaModix, Inc.
• Original Assignee: MetaModix, Inc.
• Inventors: Belhe, Kedar R., Stangenes, Todd
• Primary Examiner(s): Zimbouski, Ariana
• Application Number:
  US14/156,209
• Publication Number:
  US 20140200502A1
• Time in Patent Office: 1,805 Days
• CPC Class Codes: A61F 2/04 Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts A61F2/18, A61F2/20 take precedence; devices, other than stent-grafts, providing patency to, or preventing collapsing of, tubular structures of the body other than stent-grafts, e.g. stents A61F2/82; instruments specially adapted for placement or removal of stents or stent-grafts A61F2/95
• CPC Class Codes: A61F 2002/044 Oesophagi or esophagi or gullets
• CPC Class Codes: A61F 2002/045 Stomach, intestines
• CPC Class Codes: A61F 5/0076 preventing normal digestion, e.g. Bariatric or gastric sleeves
• CPC Class Codes: A61K 35/741 Probiotics probiotic yeast, e.g. saccharomyces A61K36/06

Abstract

Described is a system for affecting intestinal microbial flora. The system includes an intestinal sleeve that is implanted in a patient and bypasses a section of the intestine; and probiotics, prebiotics or pharmacologic therapy used in combination with the intestinal sleeve. Also described are related methods.

Claims

1. A system for treating obesity and diabetes, the system comprising:

a removable intestinal sleeve configured to be implanted along a treatment length of an intestine of a patient to prevent nutrients from contacting a lining of the intestine along the treatment length, such that an initial microbial population along the treatment length of the patient'"'"'s intestine is reduced without the use of antibiotics, wherein the intestinal sleeve is impregnated or coated with a probiotic therapy such that the probiotic therapy is deliverable at least to the treatment length of the intestine of the patient to promote beneficial intestinal microbial flora at least along the treatment length of the intestine of the patient while the intestinal sleeve is implanted and after the intestinal sleeve is removed.

2. The system of claim 1, further comprising an anchoring element attached to the sleeve, wherein the sleeve is configured to be anchored at a pyloric junction of a patient by the anchoring element.

3. The system of claim 2, wherein the anchoring element comprises two flanges, with one flange configured to be located on an intestinal side and one flange configured to be located on a stomach side of a patient when implanted.

4. The system of claim 2, wherein the anchoring element is made from Nitinol.

5. The system of claim 2, wherein the anchoring element further comprises a covering comprising a biocompatible polymer or fabric.